Quick Answer
TG THERAPEUTICS, INC. reported Diluted EPS of $2.77 per share for fiscal year 2025.
TG THERAPEUTICS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $2.77 | +1746.7% |
| 2024 | $0.15 | +66.7% |
| 2023 | $0.09 | +105.5% |
| 2022 | -$1.65 | +37.3% |
| 2021 | -$2.63 | -8.7% |
| 2020 | -$2.42 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.43 | +12050.0% | +1329.4% |
| June 30, 2025 | $0.17 | +325.0% | +466.7% |
| March 31, 2025 | $0.03 | +142.9% | +50.0% |
| September 30, 2024 | $0.02 | -97.3% | -50.0% |
| June 30, 2024 | $0.04 | +111.8% | +157.1% |
| March 31, 2024 | -$0.07 | +75.0% | -109.6% |
| September 30, 2023 | $0.73 | +380.8% | +314.7% |
| June 30, 2023 | -$0.34 | -13.3% | -21.4% |
- TG THERAPEUTICS, INC. showed an increase of +1746.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, TG THERAPEUTICS, INC.’s diluted eps has grown by 214.5% (from $2.42 per share (loss) to $2.77 per share).
- The most recent figure is from TG THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: